Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carole Ayav

Showing results (31-40 of 55) with videos related to

Pageof 6
Sort By:
Nephrologie & Therapeutique|December 4, 2015
[T2HD Study. Oral anticoagulants and antiplatelet agents: Practices, benefits, and risks in the chronic hemodialysis population. Observational data]Alexandre Martin, Nathalie Thilly, Carole Ayav, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|February 10, 2021
Kidney function monitoring to prevent 5-aminosalicylic acid nephrotoxicity: What the gastroenterologist should knowLucas Guillo, Ferdinando D'Amico, Hamza Achit, et al.
European Journal of Gastroenterology & Hepatology|November 30, 2020
Knowledge of 5-aminosalicylic acid nephrotoxicity and adherence to kidney function monitoring of patients with inflammatory bowel diseaseLucie Weislinger, Lucas Guillo, Ferdinando D'Amico, et al.
BMC Nephrology|February 23, 2017
Vascular access conversion and patient outcome after hemodialysis initiation with a nonfunctional arteriovenous access: a prospective registry-based studyNatalia Alencar de Pinho, Raphael Coscas, Marie Metzger, et al.
Plos One|July 28, 2017
Predictors of nonfunctional arteriovenous access at hemodialysis initiation and timing of access creation: A registry-based studyNatalia Alencar de Pinho, Raphael Coscas, Marie Metzger, et al.
Surgery|October 19, 2015
Minimal impact of calcimimetics on the management of hyperparathyroidism in chronic dialysisLaurent Brunaud, Willy Ngueyon Sime, Pierre Filipozzi, et al.
Pharmacoepidemiology and Drug Safety|May 3, 2016
Antiplatelet and oral anticoagulant therapies in chronic hemodialysis patients: prescribing practices and bleeding riskCamille Collette, Isabelle Clerc-Urmès, Hervé Laborde-Castérot, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 19, 2021
Effect of age and care organization on sources of variation in kidney transplant waiting list registrationCécile Couchoud, Florian Bayer, Muriel Rabilloud, et al.
Kidney International|August 29, 2020
Low incidence of SARS-CoV-2, risk factors of mortality and the course of illness in the French national cohort of dialysis patientsCécile Couchoud, Florian Bayer, Carole Ayav, et al.
British Journal of Clinical Pharmacology|August 16, 2018
Evaluation of the adequacy of drug prescriptions in patients with chronic kidney disease: results from the CKD-REIN cohortSolène M Laville, Marie Metzger, Bénédicte Stengel, et al.
Pageof 6

Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
Nephrologie & Therapeutique|December 4, 2015
[T2HD Study. Oral anticoagulants and antiplatelet agents: Practices, benefits, and risks in the chronic hemodialysis population. Observational data]Alexandre Martin, Nathalie Thilly, Carole Ayav, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|February 10, 2021
Kidney function monitoring to prevent 5-aminosalicylic acid nephrotoxicity: What the gastroenterologist should knowLucas Guillo, Ferdinando D'Amico, Hamza Achit, et al.
European Journal of Gastroenterology & Hepatology|November 30, 2020
Knowledge of 5-aminosalicylic acid nephrotoxicity and adherence to kidney function monitoring of patients with inflammatory bowel diseaseLucie Weislinger, Lucas Guillo, Ferdinando D'Amico, et al.
BMC Nephrology|February 23, 2017
Vascular access conversion and patient outcome after hemodialysis initiation with a nonfunctional arteriovenous access: a prospective registry-based studyNatalia Alencar de Pinho, Raphael Coscas, Marie Metzger, et al.
Plos One|July 28, 2017
Predictors of nonfunctional arteriovenous access at hemodialysis initiation and timing of access creation: A registry-based studyNatalia Alencar de Pinho, Raphael Coscas, Marie Metzger, et al.
Surgery|October 19, 2015
Minimal impact of calcimimetics on the management of hyperparathyroidism in chronic dialysisLaurent Brunaud, Willy Ngueyon Sime, Pierre Filipozzi, et al.
Pharmacoepidemiology and Drug Safety|May 3, 2016
Antiplatelet and oral anticoagulant therapies in chronic hemodialysis patients: prescribing practices and bleeding riskCamille Collette, Isabelle Clerc-Urmès, Hervé Laborde-Castérot, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 19, 2021
Effect of age and care organization on sources of variation in kidney transplant waiting list registrationCécile Couchoud, Florian Bayer, Muriel Rabilloud, et al.
Kidney International|August 29, 2020
Low incidence of SARS-CoV-2, risk factors of mortality and the course of illness in the French national cohort of dialysis patientsCécile Couchoud, Florian Bayer, Carole Ayav, et al.
British Journal of Clinical Pharmacology|August 16, 2018
Evaluation of the adequacy of drug prescriptions in patients with chronic kidney disease: results from the CKD-REIN cohortSolène M Laville, Marie Metzger, Bénédicte Stengel, et al.
Pageof 6